Mateon Therapeutics, Inc.
MATN
MATN was delisted on the 7th of December, 2016.
1 hedge funds and large institutions have $19K invested in Mateon Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 20 closing their positions.
95% less funds holding
Funds holding: 21 → 1 (-20)
99% less capital invested
Capital invested by funds: $1.42M → $19K (-$1.4M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 20
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $31K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$679K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$489K |
| 3 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$94K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$37K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$17K |
MATN Hedge Fund Activity: Q4 2016 in Review
1 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Mateon Therapeutics, Inc. (MATN) for Q4 2016, worth a combined $19K — down 99% from $1.42M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of MATN and 0 opened new positions — a net loss of 20 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Renaissance Technologies, exiting entirely with an estimated $679K sold.
- 1 institutional investor held Mateon Therapeutics, Inc. (MATN) as of Q4 2016, down from 21 in Q3 2016.
- Funds reported $19K of Mateon Therapeutics, Inc. stock for Q4 2016, down 99% quarter-over-quarter.
- 0 funds opened new Mateon Therapeutics, Inc. positions in Q4 2016 and 20 closed out, a net change of -20 holders.
- The largest Mateon Therapeutics, Inc. seller in Q4 2016 was Renaissance Technologies, an estimated $679K sold.
Based on aggregated 13F filings for Q4 2016.